UGT1A1 and Thrombocytopenia: The results showed that the incidence of grade 3–4 thrombocytopenia in the course of IRI chemotherapy was lower in UGT1A1*28 wild-type (TA6/6) than mutant type (TA6/7 + TA7/7), and the difference was statistically significant [RR = 0.16, 95%CI (0.06, 0.42), P = 0.0002], as shown in Figure 12.